A Phase I Trial of Nab-Paclitaxel in Combination With Gemcitabine for Relapsed/Refractory Pediatric Solid Tumors.

Document Type

Article

Publication Date

1-2026

Identifier

DOI: 10.1002/pbc.32102

Abstract

BACKGROUND: The single-agent pediatric maximum tolerated dose (MTD) of nab-paclitaxel is significantly higher than adult dosing. We conducted a Phase I trial to establish the MTD/recommended Phase 2 dose (RP2D) of nab-paclitaxel with gemcitabine in children with relapsed/refractory solid tumors.

METHODS: Nab-paclitaxel was administered intravenously with fixed-dose gemcitabine on days 1, 8, and 15 of 28-day cycles. Three dose levels (DL) of nab-paclitaxel, 180, 210, and 240 mg/m

RESULTS: Twenty-four patients enrolled, 22 received therapy, and 20 were evaluable for dose-limiting toxicity (DLT): 17 during dose escalation and 3 in dose expansion at the MTD. Median age was 12.5 years. Diagnoses included osteosarcoma (n = 11), neuroblastoma (n = 4), and rhabdomyosarcoma (n = 4). At the starting dose level (gemcitabine 1000 mg/m2, nab-paclitaxel 180 mg/m2), two of five patients experienced DLT, prompting an amendment lowering gemcitabine to 675 mg/m2/dose. Post-amendment, nab-paclitaxel 240 mg/m2/dose with gemcitabine 675 mg/m2/dose was identified as the MTD. Grade ≥3 hematologic toxicities were common. Two patients experienced a partial response (Wilms tumor and osteosarcoma), and PK exhibited linearity across DL. SPARC immunoreactivity was present in most tumors, while CAV-1 immunoreactivity was infrequent.

CONCLUSIONS: The MTD/RP2D of nab-paclitaxel with gemcitabine in patients with relapsed/refractory pediatric solid tumors is nab-paclitaxel 240 mg/m2/dose on days 1, 8, and 15 of 28-day cycles; responses were limited in this patient population.

Journal Title

Pediatric blood & cancer

Volume

73

Issue

1

First Page

32102

Last Page

32102

MeSH Keywords

Humans; Gemcitabine; Paclitaxel; Female; Albumins; Male; Child; Deoxycytidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Neoplasm Recurrence, Local; Child, Preschool; Maximum Tolerated Dose; Neoplasms; Osteonectin; Neuroblastoma; Prognosis; Osteosarcoma; Follow-Up Studies; Drug Resistance, Neoplasm; Rhabdomyosarcoma; Bone Neoplasms

PubMed ID

41088849

Keywords

Phase I; gemcitabine; nab‐paclitaxel; pediatric; solid tumor

Link to Full Text
Library Record

Share

COinS